Migalastat Dosing for Fabry Renal Function Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy (ERT) and pharmacological chaperones, struggle to effectively penetrate and stabilize renal function in patients with renal impairment, leading to progressive kidney damage and the need for dialysis or transplantation.
Innovation Solution
Administering migalastat, a pharmacological chaperone, to Fabry patients with renal impairment at a frequency of once every other day, ranging from 100 mg to 150 mg free base equivalent, to stabilize renal function, reduce plasma lyso-Gb3, and enhance α-Gal A activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered to Fabry patients with renal impairment, then enzyme deficiency is addressed, but the therapy fails to effectively penetrate and stabilize renal function
Solution Approach 1:
The patent changes the chemical structure parameters of the therapy from large protein-based enzymes to small molecule pharmacological chaperones (migalastat). This parameter change allows the therapy to penetrate renal tissue effectively and stabilize mutant α-Gal A enzymes, addressing the inability of ERT to stabilize renal function in patients with renal impairment.
Solution Approach 2:
The patent introduces migalastat as an intermediary substance that binds to mutant α-Gal A enzymes and facilitates their proper folding and trafficking to lysosomes. This intermediary approach overcomes the direct penetration limitation of ERT by using a small molecule carrier that can reach renal tissue and restore enzyme function.
2Reliability
If pharmacological chaperones are used to stabilize mutant enzyme, then enzyme activity is enhanced, but penetration into renal tissue with impairment is insufficient
Solution Approach 1:
The patent optimizes the molecular weight and lipophilicity parameters of migalastat to enhance its penetration capability into renal tissue. By adjusting these physical-chemical parameters, the pharmacological chaperone achieves both high enzyme activity enhancement and sufficient tissue penetration, resolving the contradiction between these two requirements.
3Stability of the object's composition
If standard dosing frequency is used, then enzyme stability is maintained, but renal function progression is not adequately slowed
Solution Approach 1:
The patent implements a periodic dosing regimen of migalastat administered every other day. This periodic action maintains sufficient enzyme stability while allowing accumulation of therapeutic effect over time, effectively slowing renal function progression in Fabry patients better than standard dosing frequencies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Migalastat therapy stabilizes renal function, reduces left ventricular mass index, and increases white blood cell α-Gal A activity, slowing the progression of renal impairment and improving overall disease outcomes in Fabry patients.
Implementation Method 1
treatment with what are called pharmacological chaperones (PCs). Such PCs include small molecule inhibitors of α-Gal A, which can bind to the α-Gal A to increase the stability of both mutant enzyme and the corresponding wild type
Implementation Method 2
Migalastat is a pharmacological chaperone that is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of a-Gal A
Data Source
Figure 1A
Figure 1B~1C
Figure 2
AI summary
Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing α-galactosidase A activity in the patient.